These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 17878251

  • 1. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [Abstract] [Full Text] [Related]

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 3. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K.
    Med Sci Monit; 2018 May 08; 24():3002-3010. PubMed ID: 29737325
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA.
    Cancer Res; 2008 Aug 01; 68(15):6145-53. PubMed ID: 18676837
    [Abstract] [Full Text] [Related]

  • 7. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 01; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 8. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.
    J Clin Endocrinol Metab; 2010 Jan 01; 95(1):450-5. PubMed ID: 19880792
    [Abstract] [Full Text] [Related]

  • 9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.
    Cancer Res; 2009 Apr 01; 69(7):3042-51. PubMed ID: 19276360
    [Abstract] [Full Text] [Related]

  • 10. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
    Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.
    Clin Cancer Res; 2008 Jan 01; 14(1):230-9. PubMed ID: 18172275
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.
    Oncotarget; 2016 May 24; 7(21):30907-23. PubMed ID: 27127178
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D.
    BMC Cancer; 2015 Mar 26; 15():184. PubMed ID: 25879531
    [Abstract] [Full Text] [Related]

  • 15. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    Liu R, Liu D, Xing M.
    J Clin Endocrinol Metab; 2012 Feb 26; 97(2):E173-82. PubMed ID: 22090271
    [Abstract] [Full Text] [Related]

  • 16. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ.
    Int J Cancer; 2009 Nov 15; 125(10):2332-41. PubMed ID: 19637312
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.
    Clin Cancer Res; 2012 May 01; 18(9):2515-25. PubMed ID: 22392911
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK, Na HJ, Yang YJ, Kwon HJ, Chang JW, Ban MJ, Kim WS, Shin DY, Lee EJ, Koh YW, Yoon JH, Choi EC.
    Mol Carcinog; 2016 Nov 01; 55(11):1678-1687. PubMed ID: 26456083
    [Abstract] [Full Text] [Related]

  • 20. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG.
    Clin Cancer Res; 2011 Mar 01; 17(5):989-1000. PubMed ID: 21245089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.